Skip to main content
Premium Trial:

Request an Annual Quote

Dutch Biosensor Firm Ostendum Adopts Scienion Arrayers for Nanodevice Manufacturing

Premium

Ostendum will use Scienion's SciFlexarrayer instrument to print its lab-on-a-chip nanodevices, Scienion said this week.

Headquartered in Enschede, the Netherlands, Ostendum sells biosensing nanodevices for the detection of microorganisms, biomarkers, biomolecules, and nanoparticles. Its tools rely on interferometric nanotechnology, a sensitive, label-free approach that enables within minutes the detection of bacteria, viruses, yeasts, proteins and DNA molecules, as well as the determination of their concentrations.

Ostendum CEO Paul Nederkoorn said in a statement that his company became aware of Scienion's arraying technology through a collaboration with food researchers at Wageningen University and Research Center, and "came to the conclusion that the SciFlexarrayer non-contact dispenser would be the best solution to precisely and accurately spot antibodies onto our nanodevices."

Established in 2000, Berlin-based Scienion offers arraying instruments and services. It has launched six distinct sciFlexarrayer instruments to date: the entry-level model DW, which can produce four arrays in one run; the S3 for R&D applications; the S5 and S11 for medium-throughput array manufacturing; the S100, which can produce more than 1,000 arrays per run for high-throughput manufacturing; and the compact SX system, which includes components from all of Scienion's arrayers in one enclosure.

Nederkoorn said that Ostendum opted to adopt Scienion's SX model because it "enables us to complete any R&D processes and to scale up for production." He added that the SX is "suitable for our future activities in developing higher multiplexed chips."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.